Senores Pharmaceuticals Limited has informed the Exchange about changes in the Senior Management Personnel ( SMP ) of the Company
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals announced two changes in its Senior Management Personnel effective May 15, 2025. Mr. Anish Makwani has been appointed and categorized as SMP in his role as General Manager – Production (Small Volume Parenteral); he brings over 33 years of pharma production experience, including a prior role as AVP – Parenteral Production at Cadila Pharmaceuticals, with expertise in ampoules, vials, pre-filled syringes, and regulatory compliance with US FDA and EU standards. Separately, Mr. Malay Rameshbhai Patel, AVP – Research & Development, resigned from the company citing his wish to pursue a new challenge. Both changes were approved by the Board on the recommendation of the Nomination and Remuneration Committee.
These are mid-level management transitions (one production hire, one R&D departure) and do not involve Key Managerial Personnel such as the CEO, CFO, or Company Secretary. The impact on the stock or shareholders is expected to be minimal and routine.